Your browser doesn't support javascript.
loading
NSD2 is a conserved driver of metastatic prostate cancer progression.
Aytes, Alvaro; Giacobbe, Arianna; Mitrofanova, Antonina; Ruggero, Katia; Cyrta, Joanna; Arriaga, Juan; Palomero, Luis; Farran-Matas, Sonia; Rubin, Mark A; Shen, Michael M; Califano, Andrea; Abate-Shen, Cory.
Afiliación
  • Aytes A; Department of Urology, Columbia University Irving Medical Center, 160 Fort Washington Ave, New York, NY, 10032, USA. aaytes@idibell.cat.
  • Giacobbe A; Programs of Molecular Mechanisms and Experimental Therapeutics in Oncology (ONCOBell), and Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, 199, 08908, Barcelona, Spain. aaytes@i
  • Mitrofanova A; Department of Urology, Columbia University Irving Medical Center, 160 Fort Washington Ave, New York, NY, 10032, USA.
  • Ruggero K; Department of Medicine, Columbia University Irving Medical Center, 630W 168th Street, New York, NY, 10032, USA.
  • Cyrta J; Department of Systems Biology, Columbia University Irving Medical Center, 1130 Saint Nicholas Ave, New York, NY, 10032, USA.
  • Arriaga J; Department of Health Informatics, Rutgers School of Health Professions, Rutgers, The State University of New Jersey, 65 Bergen Street, Newark, NJ, 07101, USA.
  • Palomero L; Programs of Molecular Mechanisms and Experimental Therapeutics in Oncology (ONCOBell), and Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, 199, 08908, Barcelona, Spain.
  • Farran-Matas S; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, USA.
  • Rubin MA; Department of Urology, Columbia University Irving Medical Center, 160 Fort Washington Ave, New York, NY, 10032, USA.
  • Shen MM; Department of Medicine, Columbia University Irving Medical Center, 630W 168th Street, New York, NY, 10032, USA.
  • Califano A; Programs of Molecular Mechanisms and Experimental Therapeutics in Oncology (ONCOBell), and Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, 199, 08908, Barcelona, Spain.
  • Abate-Shen C; Programs of Molecular Mechanisms and Experimental Therapeutics in Oncology (ONCOBell), and Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, 199, 08908, Barcelona, Spain.
Nat Commun ; 9(1): 5201, 2018 12 05.
Article en En | MEDLINE | ID: mdl-30518758
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Proteínas Represoras / N-Metiltransferasa de Histona-Lisina Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Proteínas Represoras / N-Metiltransferasa de Histona-Lisina Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido